« Previous article
Mycotoxins as Food C...

22nd June 2020  Content supplied by: ProGnosis Biotech S.A

Rapid Antibody Testing Against COVID-19: High Sensitivity & Specificity 

ProGnosis Biotech participated in a clinical performance study, which was conducted on June 12, 2020, at the School of Medicine, of the Aristotle University of Thessaloniki, which serves as one of the official reference laboratories for SARS-CoV-2 in Greece. For the evaluation, 80 positive and 114 negative, samples were examined (194 in total) and The RAPID TEST 2019-nCoV Total Ig demonstrated 98,75% sensitivity and 100% specificity for the detection of total antibodies against SARS-CoV-2. What is more, for samples that were collected after the first 7 days from the onset of the symptoms, both sensitivity and specificity reached 100%.


Developed by ProGnosis Biotech, Rapid test 2019-nCoV Total (V1210/V1230) is a qualitative Lateral Flow test for the detection of IgA, IgM, and IgG antibodies against SARS-CoV-2 in human serum, plasma or whole blood specimens.

  • Lateral flow in dip stick format available in 10 or 30 test sticks
  • Low procedure time: 10 min
  • Easy-to-use method, no need for equipment or special facilities
  • Visual interpretation of the results
  • Shelf Life: 12 months | Storage 4-30°C



Date Published: 22nd June 2020

Source article link: View

View full company details